{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:39:01Z","timestamp":1771295941876,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Chem"],"DOI":"10.1038\/s42004-025-01558-3","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T18:19:32Z","timestamp":1749925172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A mechanistic model of pure and lipidic \u03b1-synuclein aggregation for advancing Parkinson\u2019s therapies"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-4238","authenticated-orcid":false,"given":"Elena","family":"Righetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-7705","authenticated-orcid":false,"given":"Luca","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7436-6919","authenticated-orcid":false,"given":"Enrico","family":"Domenici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7891-5695","authenticated-orcid":false,"given":"Federico","family":"Reali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"1558_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1558_CR2","doi-asserted-by":"crossref","unstructured":"Soto, C. et al. Toward a biological definition of neuronal and glial synucleinopathies. Nat. Med. 31, 396\u2013408 (2025).","DOI":"10.1038\/s41591-024-03469-7"},{"key":"1558_CR3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","volume":"149","author":"N Cremades","year":"2012","unstructured":"Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein. Cell 149, 1048\u20131059 (2012).","journal-title":"Cell"},{"key":"1558_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","volume":"97","author":"F Zunke","year":"2018","unstructured":"Zunke, F. et al. Reversible conformational conversion of \u03b1-synuclein into toxic assemblies by glucosylceramide. Neuron 97, 92\u2013107 (2018).","journal-title":"Neuron"},{"key":"1558_CR5","doi-asserted-by":"publisher","first-page":"8043","DOI":"10.3390\/ijms21218043","volume":"21","author":"P Gracia","year":"2020","unstructured":"Gracia, P., Camino, J. D., Volpicelli-Daley, L. & Cremades, N. Multiplicity of \u03b1-synuclein aggregated species and their possible roles in disease. Int. J. Mol. Sci. 21, 8043 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1558_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21937-3","volume":"12","author":"R Cascella","year":"2021","unstructured":"Cascella, R. et al. The release of toxic oligomers from \u03b1-synuclein fibrils induces dysfunction in neuronal cells. Nat. Commun. 12, 1814 (2021).","journal-title":"Nat. Commun."},{"key":"1558_CR7","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.aan6160","volume":"358","author":"G Fusco","year":"2017","unstructured":"Fusco, G. et al. Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers. Science 358, 1440\u20131443 (2017).","journal-title":"Science"},{"key":"1558_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jnc.14808","volume":"150","author":"P Alam","year":"2019","unstructured":"Alam, P., Bousset, L., Melki, R. & Otzen, D. E. \u03b1-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J. Neurochem. 150, 522\u2013534 (2019).","journal-title":"J. Neurochem."},{"key":"1558_CR9","doi-asserted-by":"publisher","first-page":"7690","DOI":"10.1002\/ange.201400491","volume":"126","author":"W Paslawski","year":"2014","unstructured":"Paslawski, W., Mysling, S., Thomsen, K., J\u00f8rgensen, T. J. & Otzen, D. E. Co-existence of two different \u03b1-synuclein oligomers with different core structures determined by hydrogen\/deuterium exchange mass spectrometry. Angewandte Chem. 126, 7690\u20137693 (2014).","journal-title":"Angewandte Chem."},{"key":"1558_CR10","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1021\/ja411577t","volume":"136","author":"N Lorenzen","year":"2014","unstructured":"Lorenzen, N. et al. The role of stable \u03b1-synuclein oligomers in the molecular events underlying amyloid formation. J. Am. Chem. Soc. 136, 3859\u20133868 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"1558_CR11","doi-asserted-by":"crossref","unstructured":"Cremades, N., Chen, S. & Dobson, C. Structural characteristics of \u03b1-synuclein oligomers. Int. Rev. Cell Mol. Biol. (Academic Press, 2017).","DOI":"10.1016\/bs.ircmb.2016.08.010"},{"key":"1558_CR12","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1039\/C9SC06501F","volume":"11","author":"AJ Dear","year":"2020","unstructured":"Dear, A. J. et al. Identification of on- and off-pathway oligomers in amyloid fibril formation. Chem. Sci. 11, 6236\u20136247 (2020).","journal-title":"Chem. Sci."},{"key":"1558_CR13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian, S. H. et al. Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099\u20131109 (2019).","journal-title":"Nat. Neurosci."},{"key":"1558_CR14","doi-asserted-by":"publisher","first-page":"e77235","DOI":"10.1371\/journal.pone.0077235","volume":"8","author":"E Hellstrand","year":"2013","unstructured":"Hellstrand, E., Nowacka, A., Topgaard, D., Linse, S. & Sparr, E. Membrane lipid co-aggregation with \u03b1-synuclein fibrils. PloS ONE 8, e77235 (2013).","journal-title":"PloS ONE"},{"key":"1558_CR15","doi-asserted-by":"publisher","first-page":"10998","DOI":"10.1039\/D3CP05928F","volume":"26","author":"C Galvagnion","year":"2024","unstructured":"Galvagnion, C. et al. Structural characterisation of \u03b1-synuclein\u2013membrane interactions and the resulting aggregation using small angle scattering. Phys. Chem. Chem. Phys. 26, 10998\u201311013 (2024).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"1558_CR16","doi-asserted-by":"crossref","unstructured":"Dear, A. J. et al. Molecular mechanism of \u03b1-synuclein aggregation on lipid membranes revealed. Chem. Sci. 15, 7229\u20137242 (2024).","DOI":"10.1039\/D3SC05661A"},{"key":"1558_CR17","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1126\/science.1178250","volume":"326","author":"TP Knowles","year":"2009","unstructured":"Knowles, T. P. et al. An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533\u20137 (2009).","journal-title":"Science"},{"key":"1558_CR18","doi-asserted-by":"publisher","first-page":"909861","DOI":"10.3389\/fnins.2022.909861","volume":"16","author":"G Meisl","year":"2022","unstructured":"Meisl, G., Knowles, T. P. & Klenerman, D. Mechanistic models of protein aggregation across length-scales and time-scales: From the test tube to neurodegenerative disease. Front. Neurosci. 16, 909861 (2022).","journal-title":"Front. Neurosci."},{"key":"1558_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nprot.2016.010","volume":"11","author":"G Meisl","year":"2016","unstructured":"Meisl, G. et al. Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat. Protoc. 11, 252\u2013272 (2016).","journal-title":"Nat. Protoc."},{"key":"1558_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-023-00651-2","volume":"19","author":"DJ Rinauro","year":"2024","unstructured":"Rinauro, D. J., Chiti, F., Vendruscolo, M. & Limbocker, R. Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases. Mol. Neurodegen. 19, 1\u201332 (2024).","journal-title":"Mol. Neurodegen."},{"key":"1558_CR21","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.cell.2022.05.008","volume":"185","author":"E Hallacli","year":"2022","unstructured":"Hallacli, E. et al. The parkinson\u2019s disease protein alpha-synuclein is a modulator of processing bodies and mrna stability. Cell 185, 2035\u20132056 (2022).","journal-title":"Cell"},{"key":"1558_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","volume":"46","author":"M Sharma","year":"2023","unstructured":"Sharma, M. & Burr\u00e9, J. \u03b1-synuclein in synaptic function and dysfunction. Trends Neurosci. 46, 153\u2013166 (2023).","journal-title":"Trends Neurosci."},{"key":"1558_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-019-0095-3","volume":"5","author":"BA Killinger","year":"2019","unstructured":"Killinger, B. A., Melki, R., Brundin, P. & Kordower, J. H. Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let\u2019s talk about the lipids in the room. npj Parkinson\u2019s Dis. 5, 23 (2019).","journal-title":"npj Parkinson\u2019s Dis."},{"key":"1558_CR24","doi-asserted-by":"publisher","first-page":"1060489","DOI":"10.3389\/fams.2022.1060489","volume":"8","author":"E Righetti","year":"2022","unstructured":"Righetti, E., Antonello, A., Marchetti, L., Domenici, E. & Reali, F. Mechanistic models of \u03b1-synuclein homeostasis for parkinson\u2019s disease: A blueprint for therapeutic intervention. Front. Appl. Mathe. Stat. 8, 1060489 (2022).","journal-title":"Front. Appl. Mathe. Stat."},{"key":"1558_CR25","doi-asserted-by":"crossref","unstructured":"Geerts, H. et al. A combined pbpk and qsp model for modeling amyloid aggregation in alzheimer\u2019s disease. CPT: Pharmacometrics Syst. Pharmacol. 12, 444\u2013461 (2023).","DOI":"10.1002\/psp4.12912"},{"key":"1558_CR26","doi-asserted-by":"crossref","unstructured":"Bloomingdale, P. et al. Hallmarks of neurodegenerative disease: A systems pharmacology perspective. CPT: Pharmacometrics Syst. Pharmacol. 11, 1399\u20131429 (2022).","DOI":"10.1002\/psp4.12852"},{"key":"1558_CR27","doi-asserted-by":"crossref","unstructured":"Cassotta, M. et al. The future of Parkinson\u2019s disease research: a new paradigm of human-specific investigation is necessary\u2026 and possible. ALTEX - Alternatives to animal experimentation 2022, 694\u2013709 (2022).","DOI":"10.14573\/altex.2203161"},{"key":"1558_CR28","first-page":"335","volume":"13","author":"G Menon","year":"2024","unstructured":"Menon, G., Bakshi, S. & Krishnan, J. The interaction of core modules as a basis for elucidating network behavior determining parkinson\u2019s disease pathogenesis. CPT: Pharmacometrics Syst. Pharmacol. 13, 335 (2024).","journal-title":"CPT: Pharmacometrics Syst. Pharmacol."},{"key":"1558_CR29","doi-asserted-by":"publisher","first-page":"1351555","DOI":"10.3389\/fsysb.2024.1351555","volume":"4","author":"C Denaro","year":"2024","unstructured":"Denaro, C., Stephenson, D., M\u00fcller, M. L., Piccoli, B. & Azer, K. Advancing precision medicine therapeutics for parkinson\u2019s utilizing a shared quantitative systems pharmacology model and framework. Front. Syst. Biol. 4, 1351555 (2024).","journal-title":"Front. Syst. Biol."},{"key":"1558_CR30","doi-asserted-by":"publisher","first-page":"E1206","DOI":"10.1073\/pnas.1524128113","volume":"113","author":"M Iljina","year":"2016","unstructured":"Iljina, M. et al. Kinetic model of the aggregation of \u03b1-synuclein provides insights into prion-like spreading. Proc. Natl. Acad. Sci. USA 113, E1206\u2013E1215 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1558_CR31","doi-asserted-by":"crossref","unstructured":"Dear, A. J. et al. Kinetic diversity of amyloid oligomers. Proc. Natl. Acad. Sci. USA 117, 12087\u20131294 (2020).","DOI":"10.1073\/pnas.1922267117"},{"key":"1558_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nchembio.1750","volume":"11","author":"C Galvagnion","year":"2015","unstructured":"Galvagnion, C. et al. Lipid vesicles trigger \u03b1-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11, 229\u2013234 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"1558_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0022-2836(62)80112-0","volume":"4","author":"F Oosawa","year":"1962","unstructured":"Oosawa, F. & Kasai, M. A theory of linear and helical aggregations of macromolecules. J. Mol. Biol. 4, 10\u201321 (1962).","journal-title":"J. Mol. Biol."},{"key":"1558_CR34","doi-asserted-by":"crossref","unstructured":"Gaspar, R. et al. Secondary nucleation of monomers on fibril surface dominates \u03b1-synuclein aggregation and provides autocatalytic amyloid amplification. Q. Rev. Biophys. 50, e6 (2017).","DOI":"10.1017\/S0033583516000172"},{"key":"1558_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50692-4","volume":"15","author":"CK Xu","year":"2024","unstructured":"Xu, C. K. et al. \u03b1-synuclein oligomers form by secondary nucleation. Nat. Commun. 15, 7083 (2024).","journal-title":"Nat. Commun."},{"key":"1558_CR36","doi-asserted-by":"publisher","first-page":"7671","DOI":"10.1073\/pnas.1315346111","volume":"111","author":"AK Buell","year":"2014","unstructured":"Buell, A. K. et al. Solution conditions determine the relative importance of nucleation and growth processes in \u03b1-synuclein aggregation. Proc. Natl. Acad. Sci. 111, 7671\u20137676 (2014).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1558_CR37","doi-asserted-by":"publisher","first-page":"10392","DOI":"10.1074\/jbc.RA119.007743","volume":"294","author":"JM Froula","year":"2019","unstructured":"Froula, J. M. et al. Defining \u03b1-synuclein species responsible for Parkinson\u2019s disease phenotypes in mice. J. Biol. Chem. 294, 10392\u201310406 (2019).","journal-title":"J. Biol. Chem."},{"key":"1558_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-020-00368-6","volume":"15","author":"BA Hijaz","year":"2020","unstructured":"Hijaz, B. A. & Volpicelli-Daley, L. A. Initiation and propagation of \u03b1-synuclein aggregation in the nervous system. Mol. Neurodegen. 15, 1\u201312 (2020).","journal-title":"Mol. Neurodegen."},{"key":"1558_CR39","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1021\/acschemneuro.3c00282","volume":"14","author":"RI Horne","year":"2023","unstructured":"Horne, R. I. et al. Secondary processes dominate the quiescent, spontaneous aggregation of \u03b1-synuclein at physiological ph with sodium salts. ACS Chem. Neurosci. 14, 3125\u20133131 (2023).","journal-title":"ACS Chem. Neurosci."},{"key":"1558_CR40","doi-asserted-by":"publisher","first-page":"562241","DOI":"10.3389\/fcell.2020.562241","volume":"8","author":"M Kiechle","year":"2020","unstructured":"Kiechle, M., Grozdanov, V. & Danzer, K. M. The role of lipids in the initiation of \u03b1-synuclein misfolding. Front. Cell Dev. Biol. 8, 562241 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1558_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37561-2","volume":"14","author":"R Rosado-Ramos","year":"2023","unstructured":"Rosado-Ramos, R. et al. Genipin prevents alpha-synuclein aggregation and toxicity by affecting endocytosis, metabolism and lipid storage. Nat. Commun. 14, 1918 (2023).","journal-title":"Nat. Commun."},{"key":"1558_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","volume":"12","author":"CR Fields","year":"2019","unstructured":"Fields, C. R., Bengoa-Vergniory, N. & Wade-Martins, R. Targeting alpha-synuclein as a therapy for Parkinson\u2019s disease. Front. Mol. Neurosci. 12, 299 (2019).","journal-title":"Front. Mol. Neurosci."},{"key":"1558_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32797-w","volume":"13","author":"L Antonschmidt","year":"2022","unstructured":"Antonschmidt, L. et al. The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils. Nat. Commun. 13, 5385 (2022).","journal-title":"Nat. Commun."},{"key":"1558_CR44","doi-asserted-by":"publisher","first-page":"e2201910120","DOI":"10.1073\/pnas.2201910120","volume":"120","author":"TC Schwarz","year":"2023","unstructured":"Schwarz, T. C. et al. High-resolution structural information of membrane-bound \u03b1-synuclein provides insight into the moa of the anti-parkinson drug ucb0599. Proc. Natl. Acad. Sci. USA 120, e2201910120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1558_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12915-017-0390-6","volume":"15","author":"M Iljina","year":"2017","unstructured":"Iljina, M. et al. Nanobodies raised against monomeric \u03b1-synuclein inhibit fibril formation and destabilize toxic oligomeric species. BMC Biol. 15, 1\u201314 (2017).","journal-title":"BMC Biol."},{"key":"1558_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s42004-020-00412-y","volume":"3","author":"R Staats","year":"2020","unstructured":"Staats, R. et al. Screening of small molecules using the inhibition of oligomer formation in \u03b1-synuclein aggregation as a selection parameter. Commun. Chem. 3, 191 (2020).","journal-title":"Commun. Chem."},{"key":"1558_CR47","doi-asserted-by":"crossref","unstructured":"Horne, R. I. et al. Discovery of potent inhibitors of \u03b1-synuclein aggregation using structure-based iterative learning. Nat. Chem. Biol. 20, 634\u2013645 (2024).","DOI":"10.1038\/s41589-024-01580-x"},{"key":"1558_CR48","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","volume":"13","author":"M Perni","year":"2018","unstructured":"Perni, M. et al. Multistep inhibition of \u03b1-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine. ACS Chem. Biol. 13, 2308\u20132319 (2018).","journal-title":"ACS Chem. Biol."},{"key":"1558_CR49","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s42003-020-01140-8","volume":"3","author":"R Limbocker","year":"2020","unstructured":"Limbocker, R. et al. Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism. Commun. Biol. 3, 435 (2020).","journal-title":"Commun. Biol."},{"key":"1558_CR50","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1021\/cn3001312","volume":"4","author":"M Rabe","year":"2013","unstructured":"Rabe, M. et al. On-surface aggregation of \u03b1-synuclein at nanomolar concentrations results in two distinct growth mechanisms. ACS Chem. Neurosci. 4, 408\u2013417 (2013).","journal-title":"ACS Chem. Neurosci."},{"key":"1558_CR51","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1126\/science.1252884","volume":"344","author":"BG Wilhelm","year":"2014","unstructured":"Wilhelm, B. G. et al. Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science 344, 1023\u20131028 (2014).","journal-title":"Science"},{"key":"1558_CR52","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jmb.2007.01.072","volume":"367","author":"P Picotti","year":"2007","unstructured":"Picotti, P. et al. Amyloid fibril formation and disaggregation of fragment 1-29 of apomyoglobin: insights into the effect of ph on protein fibrillogenesis. J. Mol. Biol. 367, 1237\u20131245 (2007).","journal-title":"J. Mol. Biol."},{"key":"1558_CR53","doi-asserted-by":"publisher","first-page":"2200086","DOI":"10.1002\/bies.202200086","volume":"44","author":"A Bigi","year":"2022","unstructured":"Bigi, A., Cascella, R., Chiti, F. & Cecchi, C. Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases. Bioessays 44, 2200086 (2022).","journal-title":"Bioessays"},{"key":"1558_CR54","doi-asserted-by":"publisher","first-page":"34272","DOI":"10.1074\/jbc.M109.049809","volume":"284","author":"W-F Xue","year":"2009","unstructured":"Xue, W.-F. et al. Fibril fragmentation enhances amyloid cytotoxicity. J. Biol. Chem. 284, 34272\u201334282 (2009).","journal-title":"J. Biol. Chem."},{"key":"1558_CR55","doi-asserted-by":"crossref","unstructured":"Thompson, T. B., Meisl, G., Knowles, T. P. & Goriely, A. The role of clearance mechanisms in the kinetics of pathological protein aggregation involved in neurodegenerative diseases. J. Chem. Phys. 154, 125101 (2021).","DOI":"10.1063\/5.0031650"},{"key":"1558_CR56","first-page":"62","volume":"12","author":"V Ramakrishnan","year":"2023","unstructured":"Ramakrishnan, V. et al. Quantitative systems pharmacology model of the amyloid pathway in alzheimer\u2019s disease: Insights into the therapeutic mechanisms of clinical candidates. CPT: Pharmacometrics Syst. Pharmacol. 12, 62\u201373 (2023).","journal-title":"CPT: Pharmacometrics Syst. Pharmacol."},{"key":"1558_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41382-0","volume":"13","author":"H Geerts","year":"2023","unstructured":"Geerts, H., Bergeler, S., Walker, M., Van der Graaf, P. H. & Courade, J.-P. Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model. Sci. Rep. 13, 14342 (2023).","journal-title":"Sci. Rep."},{"key":"1558_CR58","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano, G. et al. Trial of prasinezumab in early-stage parkinson\u2019s disease. N. Engl. J. Med. 387, 421\u2013432 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1558_CR59","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang, A. E. et al. Trial of cinpanemab in early parkinson\u2019s disease. N. Engl. J. Med. 387, 408\u2013420 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1558_CR60","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1021\/ja412105t","volume":"136","author":"S Campioni","year":"2014","unstructured":"Campioni, S. et al. The presence of an air\u2013water interface affects formation and elongation of \u03b1-synuclein fibrils. J. Am. Chem. Soc. 136, 2866\u20132875 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"1558_CR61","first-page":"6","volume":"3","author":"F Reali","year":"2017","unstructured":"Reali, F., Priami, C. & Marchetti, L. Optimization algorithms for computational systems biology. Front. Appl. Mathe. Stat. 3, 6 (2017).","journal-title":"Front. Appl. Mathe. Stat."}],"container-title":["Communications Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01558-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01558-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01558-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T06:02:12Z","timestamp":1749967332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01558-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1038\/s42004-025-01558-3","relation":{},"ISSN":["2399-3669"],"issn-type":[{"value":"2399-3669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}